Three new drugs for type 2 diabetes
Relevant BNF section: 6.1.2.3
For many patients with type 2 diabetes mellitus, metformin plus appropriate treatment for cardiovascular risk factors form the cornerstone of drug therapy.1 However, the progressive impairment of both the secretion and action of insulin in the condition mean that high blood glucose concentrations usually worsen over time, so necessitating escalation of hypoglycaemic therapy.1 Three drugs in two new classes that act on the hormonal regulation of insulin secretion have been launched recently for use as add-in therapies in patients with type 2 diabetes:
exenatide (Byetta – Eli Lilly),
sitagliptin (Januvia – MSD), and
vildagliptin (Galvus – Novartis). Here we consider whether they have a role in the management of such individuals.
This article has been cited by other articles:
-
(2008). Tests for equivalence or non-inferiority - why?. DTB
46: 55-56
[Abstract] [Full Text]
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
